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Purpose of the study
In the randomised, controlled, Phase III TITAN trial, at
week 96, significantly more patients on darunavir co-
administered with low-dose ritonavir (DRV/r) than on
lopinavir/r (LPV/r) achieved HIV-1 RNA <400 copies/mL
(67.5% vs. 59.5%; difference 8%, 95% CI 0.1–15.8), con-
firming non-inferiority (p < 0.001) and superiority of
DRV/r over LPV/r (p = 0.034). A detailed resistance char-
acterisation of virological failures (VFs) was performed.
Methods
Treatment-experienced, LPV-naïve patients with HIV-1
RNA >1,000 copies/mL were randomised to DRV/r 600/
100 mg BID (n = 298) or LPV/r 400/100 mg BID (n = 297)
combined with an optimised background regimen (NRTIs
± NNRTI). VFs were defined as patients who lost or never
achieved HIV-1 RNA <400 copies/mL after week 16. Gen-
otyping and phenotyping (Antivirogram®) were per-
formed by Virco.
Summary of results
The VF rate in the LPV/r arm (25.6%, n = 76) was higher
than in the DRV/r arm (13.8%, n = 41). Among VFs with
an available genotype at baseline and endpoint (72 for
LPV/r and 39 for DRV/r), more patients developed pri-
mary protease inhibitor (PI) mutations at end-point in
the LPV/r arm (n = 25) than in the DRV/r arm (n = 7). Pri-
mary PI mutations developing in DRV/r VFs were V32I in
three patients, I47V and L76V in two patients and M46I,
I54L, I54M and L90M in one patient. All but the M46I and
L90M mutations were 2007 DRV RAMs. In addition, more
VFs developed NRTI RAMs in the LPV/r arm (n = 20) than
in the DRV/r arm (n = 4). Phenotypically, more LPV/r VFs
than DRV/r VFs lost susceptibility to the study PI (17/55
vs. 3/36) or any PI (25/69 vs. 7/37). Among the DRV/r
VFs, the majority retained susceptibility to amprenavir
(31/31), atazanavir (29/30), indinavir (31/32), LPV (33/
33), nelfinavir (24/26), saquinavir (31/31) and tipranavir
(34/35). Furthermore, more LPV/r VFs than DRV/r VFs
lost susceptibility to the NRTI(s) used in the OBR (20/55
vs. 4/35) or any NRTI (27/66 vs. 7/38). Similar results
were obtained when patients with LPV FC >10 or patients
who previously used ≥2 PIs were excluded from the anal-
ysis.
Conclusion
In this treatment-experienced, LPV-naïve patient popula-
tion, the overall VF rate with DRV/r was half compared to
LPV/r. Furthermore, the majority of DRV/r VFs did not
develop primary PI mutations or NRTI RAMs and pre-
served susceptibility to PIs and NRTIs.
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